- Home
- BJRI vs PACB Comparison
BJRI vs PACB Comparison
Compare BJRI & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BJRI | PACB |
|---|---|---|
| Founded | 1978 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 871.2M | 715.5M |
| IPO Year | 1996 | 2010 |
Fundamental Metrics
Financial Performance| Metric | BJRI | PACB |
|---|---|---|
| Price | $39.33 | $1.73 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $37.67 | $2.08 |
| AVG Volume (30 Days) | 478.4K | ★ 6.4M |
| Earning Date | 10-30-2025 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 6.21 | N/A |
| EPS | ★ 1.34 | N/A |
| Revenue | ★ $1,388,066,000.00 | $154,584,000.00 |
| Revenue This Year | $5.06 | $4.48 |
| Revenue Next Year | $2.66 | $11.99 |
| P/E Ratio | $29.69 | ★ N/A |
| Revenue Growth | ★ 3.85 | N/A |
| 52 Week Low | $28.46 | $0.85 |
| 52 Week High | $47.02 | $2.73 |
Technical Indicators
Market Signals| Indicator | BJRI | PACB |
|---|---|---|
| Relative Strength Index (RSI) | 52.98 | 38.00 |
| Support Level | $38.91 | $1.67 |
| Resistance Level | $41.33 | $1.89 |
| Average True Range (ATR) | 1.12 | 0.13 |
| MACD | -0.23 | -0.06 |
| Stochastic Oscillator | 38.67 | 7.50 |
Price Performance
Historical ComparisonAbout BJRI BJ's Restaurants Inc.
BJ's Restaurants Inc is involved in the business of owning and operating restaurants. The company operates in a single operating segment that is full-service company-owned restaurants. It has geographic presence only in the United States of America.
About PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.